Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Chugai describes 24-oxo-22-oxavitamin D3 derivatives

July 26, 1996

FDA approval granted for Candela's ALEXlazr

July 19, 1996

Vanguard Medica exercises worldwide rights to VML-262

July 19, 1996

Penederm files FDA amendment regarding Avita

July 19, 1996

Taro's clobetasol propionate approved by FDA

July 19, 1996

Stiefel to develop and market CytoMed's CMI-392

July 19, 1996

OncorPharm acquires rights to dithymidine-based products

July 12, 1996

ProCyte seeks FDA marketing clearance for OsmoCyte

July 12, 1996

FDA issues nonapprovable letter for Avita; development elsewhere on track

July 5, 1996

ProCyte launches Iamin gel in U.S.

July 5, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...